A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Cancer Research UK
ClinicalTrials.gov Identifier:
NCT01561911
First received: March 21, 2012
Last updated: April 23, 2013
Last verified: April 2013
  Purpose

The Purpose of this study is to evaluate the safety and tolerability, and the biological effects of the chimeric anti-CD40 monoclonal antibody Chi Lob 7/4, given intravenously, weekly for 4 weeks in the treatment of patients with advanced malignancies refractory to conventional anti-cancer treatment.


Condition Intervention Phase
Cancer
Neoplasms
Lymphoma
Non-Hodgkin
B-Cell
Drug: Chi Lob 7/4 (A chimeric monoclonal antibody)
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Masking: Open Label
Official Title: A Phase I Clinical Research Study Evaluating the Safety, Tolerability and Biological Effects of the Chimeric Anti-CD40 Monoclonal Antibody Chi Lob 7/4 Given Intravenously, Weekly for Four Weeks in the Treatment of Patients With Advanced Malignancies Refractory to Conventional Anti-cancer Treatment.

Resource links provided by NLM:


Further study details as provided by Cancer Research UK:

Primary Outcome Measures:
  • 1. To establish the Maximum tolerated dose (MTD)of ChiLob 7/4 ; [ Designated as safety issue: Yes ]
    Defined as the dose below the dose at which no more 30% (2 of up to 6 patients in the cohort) , experienced a DLT (Dose Limiting Toxicity) due to ChiLob 7/4 occurring during the treatment period and up to 4 week's post treatment.

  • 2. To determine the Biologically Active Dose of Chi Lob 7/4, which is defined as the dose level at which peripheral blood B-cells are reduced by the end of therapy to 10% or less of the starting number. [ Designated as safety issue: No ]
  • 3. To determine the toxicity profile of Chi Lob 7/4 (CTCAE version 3.0) and to identify the dose limiting toxicity [ Designated as safety issue: Yes ]
  • 4. To propose a safe dose for Phase II evaluation [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • 1. To examine the Biological effects of ChiLob 7/4 Treatment [ Designated as safety issue: No ]
  • 2. To examine the Pharmacokinetics of ChiLob 7/4 treatment: (Measurement of Serum Chi Lob 7/4) [ Designated as safety issue: No ]
  • 3. To examine the Possible Anti-Tumour activity of Chi Lob 7/4 (RECIST 1.0 criteria) [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: July 2007
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Chi Lob 7/4 (A chimeric monoclonal antibody)
    3 patients will receive treatment at each dose level. Escalation from one treatment dose level to another will only be permitted once at least 3 patients have completed treatment without any DLTs. Starting weekly dose of Chi Lob 7/4 will be 0.5mg (giving a total dose per patient of 2mg divided over 4 weeks). Subsequent individual, weekly dose levels of 1.6mg, 5mg, 16mg, 50mg and 160mg (resulting in total patient doses of 6.4mg, 20mg, 64mg 200mg and 640mg respectively). Further dose escalation can continue to 240mg and 320mg dose per week (resulting in 960mg and 1280mg. Patients may be treated at a lower or intermediate dose level to define the MTD/BAD.
Detailed Description:

The primary objective of the study is to establish the safety and maximum tolerated dose of Chi Lob 7/4. In line with other established antineoplastic, chimeric monoclonal antibody therapies such as Rituximab, Chi Lob 7/4 will be given by slow intravenous infusion once every week for a total of four weeks. This treatment regimen will facilitate early, rapid and dose dense administration of antibody to a patient group with advanced malignancy refractory to conventional treatment. The starting dose for each infusion of Chi Lob 7/4 will be 0.5mg (giving a total dose per patient of 2mg divided over 4 weeks). Escalation from one treatment dose level to another will only be permitted when at least 3 patients have completed treatment without dose limiting toxicity.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically proven CD40 expressing solid tumours or diffuse large B-cell non-Hodgkin‟s lymphoma refractory to conventional treatment, or for which no conventional therapy exists.
  • Written informed consent and the ability of the patient to co-operate with treatment and follow up must be ensured and documented.
  • Age greater than 18 years.
  • Life expectancy of at least 12 weeks.
  • World Health Organisation (WHO) performance status of 0-1 (Appendix 1).
  • Haematological and biochemical indices (These measurements must be performed within one week prior to the patient going on study.)

    • Haemoglobin (Hb) ≥ 9.0 g/dl
    • Neutrophils ≥ 1 x 10^9/L
    • Total Lymphocyte count ≥ 0.5 x 10^9/L
    • Platelets (Plts) ≥ 75 x 10^9/L
    • The following baseline liver function tests :

      • Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)
      • Alanine amino-transferase (ALT) and/or aspartate amino-transferase (AST) ≤ 3 x ULN unless due to tumour in which case up to 5 x ULN is permissible
    • The following baseline renal function test:

      • calculated creatinine clearance ≥ 40 mL/min (uncorrected value) or isotope clearance measurement ≥ 40mL/min
  • Female patients of child-bearing potential are eligible, provided they have a negative serum or urine pregnancy test prior to enrolment and agree to use appropriate medically approved contraception for four weeks prior to entering the trial, during the trial and for six months afterwards.
  • Male patients must agree to use appropriate medically approved contraception during the trial and for six months afterwards.

Exclusion Criteria:

  • CD40 negative tumours by immunohistochemistry.
  • Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosoureas and mitomycin-C) prior to treatment.
  • All toxic manifestations of previous treatment must have resolved. Exceptions to this are alopecia or certain Grade 1 toxicities which in the opinion of the Investigator and Cancer Research UK should not exclude the patient.
  • Pregnant and lactating women are excluded.
  • Major thoracic and/or abdominal surgery in the preceding four weeks from which the patient has not yet recovered.
  • Patients with primary brain tumours or clinically apparent brain metastases.
  • Patients who are high medical risks because of non-malignant systemic disease including active uncontrolled infection.
  • Patients with any other condition which in the Investigator‟s opinion would not make the patient a good candidate for the clinical trial.
  • Patients known to be serologically positive for Hepatitis B, Hepatitis C or Human Immunodeficiency Virus (HIV).
  • Long term immunosuppression or steroids (for more than one month)
  • History of significant and serious allergy.
  • Concurrent congestive heart failure or prior history of class III/ IV cardiac disease (New York Heart Association [NYHA] - refer to Appendix 4)
  • Patients with low grade or transformed non-Hodgkin‟s lymphoma.
  • Prior treatment with murine monoclonal antibodies. (Prior treatment with chimeric or fully human antibodies will not exclude a patient).
  • A history of clinically significant autoimmune disease.
  • Current malignancies at other sites, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for five years and are deemed at low risk for recurrence, are eligible for the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01561911

Locations
United Kingdom
Cancer Research UK Institute for Cancer Studies, University of Birmingham
Edgbaston, Birmingham, United Kingdom, B15 2TT
Cancer Research UK Medical Oncology Unit, Southampton General Hospital
Tremona Road,, Southampton, United Kingdom, SO16 6YD
Sponsors and Collaborators
Cancer Research UK
Investigators
Principal Investigator: Peter W Johnson, Professor Cancer Research UK Medical Oncology Unit, Southampton General Hospital,
  More Information

Additional Information:
No publications provided

Responsible Party: Cancer Research UK
ClinicalTrials.gov Identifier: NCT01561911     History of Changes
Other Study ID Numbers: PH1/103
Study First Received: March 21, 2012
Last Updated: April 23, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
United Kingdom: Research Ethics Committee

Keywords provided by Cancer Research UK:
Clinical Trial
Phase I
Antibodies
Monoclonal

Additional relevant MeSH terms:
Neoplasms
Lymphoma
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 28, 2014